Am J Kidney Dis:CKD患者2型糖尿病分析

2018-09-08 xing.T MedSci原创

由此可见,CKD患者的T2DM发病率显著高于一般人群,这支持了对该人群应保持更高的警惕性。血糖控制指标和DM的家族史与T2DM事件独立相关。

很少有研究评估慢性肾病(CKD)中的2型糖尿病(T2DM)。近日,肾脏病领域权威杂志Am J Kidney Dis上发表了一篇研究文章,研究人员的目标是使用几种替代的血糖控制指标来评估CKD患者中T2DM的发生率和危险因素。

该研究为一项前瞻性队列研究,1713名参与者在基线时肾小球滤过率降低且无糖尿病,他们参与了慢性肾功能不全队列(CRIC)研究。研究人员收集了受试者肾功能和损伤指标、空腹血糖、血红蛋白A1c(HbA1c)、HOMA-IR(稳态模型评估的胰岛素抵抗)、人口统计学指标、糖尿病家族史(DM)、吸烟状况、药物使用、收缩压、甘油三酯水平、高密度脂蛋白胆固醇水平、体重指数和身体活动。该研究的结局为T2DM(定义为空腹血糖≥126mg/dL或处方中包含胰岛素或口服降糖药)。研究人员使用κ评估了空腹血糖和HbA1c水平之间的一致性。特定原因风险建模将死亡和终末期肾病作为竞争事件,用于预测T2DM事件。

总的T2DM发病率为17.81例/1000人每年。空腹血糖和HbA1c水平之间的一致性较低(对于空腹血糖和HbA1c的κ=18%)。未经调整的肾功能和损伤指标与T2DM事件之间的相关性无显著性(P≥0.4)。在多变量模型中,T2DM与空腹血糖水平(P=0.002)和DM家族史(P=0.03)之间显著相关。经调整的HOMA-IR与T2DM之间的相关性与空腹血糖水平相当; HbA1c水平的相关性无显著性(P≥0.1)。模型的Harrell’C范围从0.65到0.68。

由此可见,CKD患者的T2DM发病率显著高于一般人群,这支持了对该人群应保持更高的警惕性。血糖控制指标和DM的家族史与T2DM事件独立相关。

原始出处:

Christopher Jepson,et al. Incident Type 2 Diabetes Among Individuals With CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis.2018. https://www.ajkd.org/article/S0272-6386(18)30823-0/fulltext

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2012792, encodeId=6fdc2012e92f7, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Dec 30 06:41:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768847, encodeId=f5f81e6884757, content=<a href='/topic/show?id=51cd4e9650' target=_blank style='color:#2F92EE;'>#CKD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4796, encryptionId=51cd4e9650, topicName=CKD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fa237912269, createdName=12498f17m78暂无昵称, createdTime=Sat Nov 10 11:41:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603121, encodeId=b77a16031216b, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Mon Sep 10 01:41:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041829, encodeId=8a8d10418295c, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Sep 08 13:41:00 CST 2018, time=2018-09-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2012792, encodeId=6fdc2012e92f7, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Dec 30 06:41:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768847, encodeId=f5f81e6884757, content=<a href='/topic/show?id=51cd4e9650' target=_blank style='color:#2F92EE;'>#CKD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4796, encryptionId=51cd4e9650, topicName=CKD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fa237912269, createdName=12498f17m78暂无昵称, createdTime=Sat Nov 10 11:41:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603121, encodeId=b77a16031216b, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Mon Sep 10 01:41:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041829, encodeId=8a8d10418295c, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Sep 08 13:41:00 CST 2018, time=2018-09-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2012792, encodeId=6fdc2012e92f7, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Dec 30 06:41:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768847, encodeId=f5f81e6884757, content=<a href='/topic/show?id=51cd4e9650' target=_blank style='color:#2F92EE;'>#CKD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4796, encryptionId=51cd4e9650, topicName=CKD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fa237912269, createdName=12498f17m78暂无昵称, createdTime=Sat Nov 10 11:41:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603121, encodeId=b77a16031216b, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Mon Sep 10 01:41:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041829, encodeId=8a8d10418295c, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Sep 08 13:41:00 CST 2018, time=2018-09-08, status=1, ipAttribution=)]
    2018-09-10 gwc389
  4. [GetPortalCommentsPageByObjectIdResponse(id=2012792, encodeId=6fdc2012e92f7, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Dec 30 06:41:00 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1768847, encodeId=f5f81e6884757, content=<a href='/topic/show?id=51cd4e9650' target=_blank style='color:#2F92EE;'>#CKD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4796, encryptionId=51cd4e9650, topicName=CKD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fa237912269, createdName=12498f17m78暂无昵称, createdTime=Sat Nov 10 11:41:00 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603121, encodeId=b77a16031216b, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Mon Sep 10 01:41:00 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041829, encodeId=8a8d10418295c, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Sep 08 13:41:00 CST 2018, time=2018-09-08, status=1, ipAttribution=)]
    2018-09-08 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

Clin J Am Soc Nephrol:CKD患者是否需忌烟忌酒?

既往研究显示,烟草、酒精和非法药物使用与慢性肾病(CKD)相关。2018年7月,发表在《Clin J Am Soc Nephrol》的一项研究调查了烟草、酒精和非法药物使用与CKD进展的相关性。

J Am Soc Nephrol:ACEI早期蛋白尿降低可预测CKD患儿的肾存活?

2018年8月,发表在《J Am Soc Nephrol》的一项由荷兰和德国学者进行的研究,考察了血管紧张素转换酶抑制剂(ACEI)初始降低蛋白尿作用在CKD患儿中能否获得同成人一样的肾保护作用。

J Am Soc Nephrol:年龄和肾功能不同的晚期CKD老年患者,透析vs药物对生存期的影响

2018年8月,发表在《J Am Soc Nephrol》的一项由美国学者进行的分析,在不同年龄和肾功能的晚期CKD老年患者中,考察了透析vs药物管理与生存期之间的相关性

2018年ICRNM现场精彩呈现:Adamasco Cupisti教授漫谈肾病营养治疗

提高医疗团队对酮酸治疗的认知水平,同时大力推行酮酸治疗的患者教育,是现阶段CKD患者管理的重点。

2018年ICRNM现场精彩呈现:余学清教授剖析PEW研究进展

越来越多的研究已经证明,酮酸疗法对于预防PEW的发生和保护RRF起着积极正面的作用,值得临床推广。

2018年ICRNM现场精彩呈现:Denis Fouque解析饮食如何影响CKD的治疗结局

酮酸结合低蛋白饮食治疗应用于CKD3~4期患者的治疗时,可以有效地改善患者的营养状态。